Who are Pentavalent rotavirus vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zostavax vaccine, Live Smallpox Vaccine, Herpes Zoster, Herpes Zoster Vaccine, Live, Live attenuated HAV vaccine, RotaTeq™ (V260).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pentavalent-rotavirus-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pentavalent rotavirus vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pentavalent rotavirus vaccine (Pentavalent rotavirus vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Pentavalent rotavirus vaccine (Pentavalent rotavirus vaccine) — Sanofi Pasteur, a Sanofi Company. A live attenuated rotavirus vaccine that stimulates immune response against five rotavirus strains to prevent rotavirus gastroenteritis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pentavalent rotavirus vaccine TARGET	Pentavalent rotavirus vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine
Zostavax vaccine	Zostavax vaccine	Oklahoma Medical Research Foundation	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Live Smallpox Vaccine	Live Smallpox Vaccine	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"	marketed	Live attenuated vaccine	Vaccinia virus antigens (envelope and intracellular proteins)
Herpes Zoster	Herpes Zoster	Canadian Immunization Research Network	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Herpes Zoster Vaccine, Live	Herpes Zoster Vaccine, Live	Changchun BCHT Biotechnology Co.	marketed	Live attenuated vaccine
Live attenuated HAV vaccine	Live attenuated HAV vaccine	Sinovac Biotech Co., Ltd	marketed	Live attenuated vaccine
RotaTeq™ (V260)	RotaTeq™ (V260)	Merck Sharp & Dohme LLC	marketed	Live attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pentavalent rotavirus vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/pentavalent-rotavirus-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab